Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.
Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes
- Views Icon Views
- Share Icon Share
Angeliki Meritsi, Dimitra Latsou, Emanuel Manesis, Ilias Gatos, Ioannis Theotokas, Pavlos Zoumpoulis, Stamatia Rapti, Eustathios Tsitsopoulos, Hariklia Moshoyianni, Spilios Manolakopoulos, Dimitrios Pektasides, Anastasia Thanopoulou; Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes. Clin Diabetes 1 July 2022; 40 (3): 327–338. https://doi.org/10.2337/cd21-0104
Download citation file: